Longboard Pharmaceuticals (LBPH) has provided an announcement.
Longboard Pharmaceuticals has revealed promising interim results from their PACIFIC OLE Study on bexicaserin, a treatment for Developmental and Epileptic Encephalopathies, showcasing a significant reduction in motor seizure frequency. This 52-week safety study also demonstrated favorable safety and tolerability profiles. As a result, Longboard is actively planning a global Phase 3 program, with further presentations on the study anticipated at upcoming medical meetings. Investors and analysts are keenly observing as these developments may signal a pivotal advancement in the treatment of these complex conditions, potentially positioning Longboard as a notable player in the pharmaceutical industry.
See more data about LBPH stock on TipRanks’ Stock Analysis page.
